FOR RESEARCH USE ONLY
Clinical trial literatureImmune research

Thymosin Alpha-1

Immunomodulatory peptide researched for immune support, vaccine adjuvant activity and viral defence protocols.

01T-cell biology02Innate immunity03Vaccine response
Molecular signature / thymosin-alpha-1
Structural identity

28-amino-acid thymic immunomodulatory sequence

Also known as

Tα1 · Thymalfasin · Zadaxin

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide derived from prothymosin alpha, originally isolated from thymus tissue. It is one of the most studied immunomodulatory peptides, with clinical use in several countries for immune restoration, hepatitis, sepsis and as a vaccine adjuvant.

The research question

Thymosin Alpha-1 affects both innate and adaptive immune activity. T-cell maturation, dendritic-cell function and cytokine regulation are key study variables, especially where immune suppression and excessive inflammation need to be distinguished.

Section 02

Mechanism & research themes

Modulates innate and adaptive immunity by promoting T-cell differentiation and maturation, enhancing dendritic-cell and natural-killer-cell activity, and normalising cytokine balance. Also upregulates toll-like receptor expression and supports Th1-polarised immune responses.

01

Enhanced T-cell maturation and Th1 immune polarisation

02

Improved dendritic-cell and natural-killer-cell activity

03

Adjuvant activity for vaccine and anti-infective research

04

Restored immune competence in age-related or stress-induced immunosenescence

05

Regulation of inflammatory cytokine balance

06

Extensive clinical safety data in approved indications outside the US

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Clinical trial literature

Human studies and regional clinical use provide a substantial safety and immunology literature. Efficacy varies by indication, and immune-marker changes do not guarantee better clinical outcomes.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 1.6mg subcutaneously twice weekly, or 1mg daily for short immune-support courses. Cycles typically run 4–12 weeks, with breaks between courses. Subcutaneous administration in the abdomen or thigh is standard.

Reported persistence

Plasma half-life approximately 2 hours; immunomodulatory effects persist for days through downstream cell signalling.

Calculator starting point

1.6 mg per reference dose

2 doses per week · 12-week cycle

2 mL default reconstitution volume

1.6 mg SC twice weekly; typical immune-support cycle 4–12 weeks.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate Thymosin Alpha-1
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 5mg vial with 2–3mL bacteriostatic water for a 1.6–2.5mg/mL working concentration. Swirl gently.

Storage reference

Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 28 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Mild injection-site reactions are the most common adverse event.

L2

Autoimmune conditions require caution due to immune-potentiating effects.

L3

Use as a standalone immune therapy should be guided by research context and monitoring.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only